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Abstract
Spinal cord injury (SCI) is a devastating neurological disease. The pathophysiological mechanisms of SCI have been reported to
be relevant to central nervous system injury such as brain injury. In this study, gene expression of the brain after SCI was
elucidated using transcriptome analysis to characterize the temporal changes in global gene expression patterns in a SCI mouse
model. Subjects were randomly classified into 3 groups: sham control, acute (3 h post-injury), and subacute (2 wk post-injury)
groups. We sought to confirm the genes differentially expressed between post-injured groups and sham control group.
Therefore, we performed transcriptome analysis to investigate the enriched pathways associated with pathophysiology of the
brain after SCI using Database for Annotation Visualization, and Integrated Discovery (DAVID), which yielded Kyoto Ency-
clopedia of Genes and Genomes (KEGG) pathway. Following enriched pathways were found in the brain: oxidative phos-
phorylation pathway; inflammatory response pathways—cytokine–cytokine receptor interaction and chemokine signaling
pathway; and endoplasmic reticulum (ER) stress-related pathways—antigen processing and presentation and mitogen-activated
protein kinase signaling pathway. Oxidative phosphorylation pathway was identified at acute phase, while inflammation response
and ER stress-related pathways were identified at subacute phase. Since the following pathways—oxidative phosphorylation
pathway, inflammatory response pathways, and ER stress-related pathways—have been well known in the SCI, we suggested a
link between SCI and brain injury. These mechanisms provide valuable reference data for better understanding pathophysio-
logical processes in the brain after SCI.
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Introduction
Spinal cord injury (SCI) is one of the most debilitating neu-
rological diseases affecting the motor, sensory, and the auto-
nomic systems.1,2 Because the pathophysiology mechanism
of SCI is not fully reported, a comprehensive approach is
important to study SCI pathogenesis.
After SCI, pathophysiological events may occur, includ-
ing acute, subacute, and chronic phases. The acute phase
happens immediately after injury and primary damage leads
to immediate physical and biochemical cellular alteration
such as hemorrhage, ischemia, and hypoxia.3,4 Subse-
quently, subacute phase, occurring over time after SCI, leads
to further damage SCI results in a rapid and extensive oxi-
dative stress reaction, which causes oxidative death of the
spinal cord neurons and reduces spinal cord blood flow that
leads to edema and inflammatory responses at subacute
phase.5,6 Moreover, SCI results in apoptosis, which severely
affect neurons, oligodendrocyte, microglia, and, perhaps,
astrocytes, as well as astrogliosis.6,7 Furthermore, the
chronic phase of SCI consists of many incidents, such as
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white matter demyelination, gray matter dissolution, connec-
tive tissue deposition, and reactive gliosis. These events lead
to glial scar formation.6
Additionally, pathophysiological mechanisms of SCI
have been further related to brain injury such as cerebral
ischemia and subarachnoid hemorrhage.8-10 Recent studies
have shown that SCI causes brain inflammation, progression
of nerve cell loss, as well as loss of brain functions such as
cognition and could lead to depression.11,12 Several studies
already have investigated the alteration of gene expression
response in the brain after SCI.13-19 Brain-derived neuro-
trophic factor (BDNF), glial cell line–derived neurotrophic
factor, and histone deacetylase 1 (HDAC1) may play an
important role in the brain reorganization after SCI;20,21 how-
ever, only little is known and further studies will be needed.
In this study, we investigated the progression of the brain
injury after SCI at acute phase (3 h post-injury) and subacute
phase (2 wk post-injury) by gene expression patterns using
transcriptome analysis. We performed and confirmed differ-
entially expressed genes (DEGs) profiling to identify
enriched Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways that will enable the demonstration of the
brain injury after SCI pathophysiological mechanism at
acute phase and subacute phase. Some candidate genes
belonged to enriched KEGG pathways and were considered
to show significant roles in the brain after SCI. These results
provide a better understanding of association between brain
injury and SCI.
Materials and Methods
Animals
For all animal experiments, CD-1 (ICR) mice were housed in
a facility accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care. The experimental
procedure was approved by the Institutional Animal Care
and Use Committee (IACUC) of Yonsei University Health
System.
Male mice of age 7 wk (Orient bio, Gyeonggi-do, South
Korea) were used and were randomly classified into 3
groups: sham control brain group (n ¼ 3), 3 h post-SCI brain
group (n ¼ 3), and 2 wk post-SCI brain group (n ¼ 3).
Spinal Cord Contusion
Animals were anesthetized with a mixture of ketamine (100
mg/kg, intraperitoneal, Yuhan, Seoul, Korea) and xylazine
(10 mg/kg, intraperitoneal), and absence of blink and with-
drawal reflexes were ensured. Body temperature was main-
tained at 37 C in a hypoxic chamber. Mice received a
dorsal laminectomy at the 9th thoracic vertebral (T9) level
to expose the spinal cord and then a moderate T9 contusive
injury by the Infinite Horizons device (Precision Systems
and Instrumentation, Lexington, NY, USA) to moderate
force of 70 kdyn. The sham control mice received only a
dorsal laminectomy without contusive injury. Afterward,
the wound was sutured in layers. Post-operative care con-
sisted of manual bladder expression twice a day until auto-
matic voiding returned spontaneously, which is generally
around 7 days. After 3 h or 2 wk following SCI, the mice
were anesthetized again with ketamine and xylazine and
perfused transcardially with normal saline for isolation of
injured brains and spinal cords. These tissues were frozen at
70 C and processed for RNA isolation.
RNA Preparation
Total RNAwas prepared from the bilateral cerebrum after SCI
using the TRIzol reagent (InvitrogenLife Technologies, Carls-
bad, CA, USA) according to the manufacturers’ protocols. For
quality control, RNA quality and quantity were evaluated by
1% agarose gel electrophoresis and the optical density (OD)
260/280 ratio was confirmed with a Nanodrop spectrophot-
ometer (Thermo Fisher Scientific, Waltham, MA, USA).
RNA Sequencing and Transcriptome Data Analysis
RNA sequencing was performed by Macrogen, Inc. (Seoul,
Korea). The messenger RNA (mRNA) was transcribed into
a library of templates. This successive cluster generation
using reagents was provided by the Illumina1 TruSeq™
(Illumina, San Diego, CA, USA) RNA Sample Preparation
Kit.22-25 We performed the transcriptome analysis by the
following procedures: RNA-seq experiment and data han-
dling procedure. The detailed procedures of RNA-seq
experiment are performed following the manufacturer’s
instruction. Firstly, there are 8 steps in TruSeq mRNA
library construction: purify and fragment mRNA, synthe-
size first strand complementary DNA (cDNA), synthesize
second strand cDNA, perform end repair, adenylate the 30
end of the DNA fragments, ligate adapters, enrich DNA
fragments, and enrich library validation. Purifying step for
the poly-A-containing mRNA molecules was carried out
using magnetic beads, which attached poly-T oligo. After
that, the cleaved RNA fragments are copied into first strand
cDNA using reverse transcriptase and random primers.
Next, synthesize second strand cDNA process removes the
RNA template and synthesizes a replaced strand to generate
double-stranded (DS) cDNA with DNA polymerase I and
Ribonuclease H (RNaseH). The end repair process converts
the overhangs resulting from fragmentation into blunt ends,
using an end repair mix (End Repair Mix [ERP]). Next, “A”
nucleotide is added to the 30 ends of the blunt fragments to
prevent them from ligating to one another during the adap-
ter ligation reaction. In the process of ligation of adapters,
multiple indexing adapters ligate to the ends of the ds
cDNA, preparing them for hybridization into a flow cell.
In the enriched DNA fragments process, we performed
polymerase chain reaction (PCR) to get enriched cDNA
library. Finally, enriched library validation was performed
for quality control analysis of the sample library and quan-
tification of the DNA library templates.26
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The second procedure of RNA sequencing is clustering
and sequencing using the Illumina. The Illumina utilizes a
unique “bridged” amplification reaction that occurs on the
surface of the flow cell. A flow cell with millions of
unique clusters is loaded into the HiSeq 2000 for auto-
mated cycles of extension and imaging. Solexa’s
sequencing-by-synthesis utilizes 4 proprietary nucleotides
possessing reversible fluorophore and termination proper-
ties.22 Each sequencing cycle occurs in the presence of all
4 nucleotides, leading to higher accuracy than methods
where only 1 nucleotide is present in the reaction mix at a
time. The next procedure is data handling, which contains
sequence quality check and data analysis. SolexaQA is a
Perl-based software package that calculates quality statis-
tics and creates visual representations of data quality from
FASTQ files generated by Illumina second-generation
sequencing technology. And then, Cufflinks assembles
transcripts, estimates their abundances, and tests for dif-
ferential expression and regulation in RNA-seq samples.
It accepts reading of aligned RNA-seq and assembles the
alignments into a parsimonious set of transcripts based on
how many reads support each one, taking into account
biases in the library preparation protocol. Transcripts with
a fold change j1.5j and P < 0.05 were considered sig-
nificant and were included in downstream analysis.
KEGG Pathway Analyses
The lists of significant DEGs (fold change  j1.5j) were
submitted to the Database for Annotation, Visualization, and
Integrated Discovery (DAVID v6.7; http://david.abcc.n
cifcrf.gov/) for KEGG pathways analysis.27-29
Quantitative Real-Time Reverse Transcription
Polymerase Chain Reaction (qRT-PCR)
DEGs of interest were selected for the validation of tran-
scriptome analysis results by qRT-PCR. Total RNA was
reverse transcribed into cDNA using ReverTra Ace1 qPCR
RT Master Mix with genomic DNA Remover (Toyobo,
Osaka, Japan) according to the manufacturer’s instructions.
The mRNA expression for genes of interest was profiled
using qPCRBIO SyGreen Mix Hi-ROX (PCR Biosystems,
London, UK) in a StepOnePlus Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). Data analysis
was performed using the 2DDCT method. Primers used for
qRT-PCR are described in Table 1.
Western Blot Analysis
To assess Cytochrome C Oxidase Subunit 7B (COX7B),
TNF Receptor Superfamily Member 25 (TNFRSF25), Heat
Shock 70 KDa Protein 1A/1B (HSPA1AB), Heat Shock
70kD Protein 5 (HSPA5), and NF-Kappa-B Inhibitor Alpha
(NFKBIA), the brain samples were homogenized and dis-
solved in radioimmunoprecipitation assay buffer (RIPA)
buffer (Thermo Fisher Scientific, Rockford, IL, USA) with
protease inhibitors (Abcam, Cambridge, UK). Total proteins
were quantified using bicinchoninic acid assay (BCA
assay)™ Protein Assay Kit (Thermo Fisher Scientific). The
samples were denatured and separated by 4% to 12% Bis-
Tris gels in 1 NuPage MES SDS running buffer (Invitro-
gen, Eugene, OR, USA). Bands were transferred onto a poly-
vinylidene difluoride (PVDF) (Invitrogen) in 20% (vol/vol)
methanol in NuPage Transfer Buffer (Invitrogen) at 4 C.
Membranes were blocked and then incubated overnight at
4 C with the following antibodies: COX7B (1:1,000,
Abcam), TNFRSF25 (1:1,000, Santa Cruz Biotechnology,
Santa Cruz, CA, USA), HSPA1AB (1:1,000, Santa Cruz
Biotechnology), HSPA5 (1:1,000, Santa Cruz Biotechnol-
ogy), NFKBIA (1:1,000, Santa Cruz Biotechnology), and
Actin (1:3,000, Santa Cruz Biotechnology). The next day,
the blots were washed 3 times with tris-buffered saline
(TBS) (Biosesang, Gyeonggi-do, Korea) plus 0.1% Tween
20 (Bio-Rad, Hercules, CA, USA) and incubated for 1 h
with horseradish peroxidase (HRP)–conjugated secondary
antibodies (1:4,000; Santa Cruz) at room temperature.
After being washed 3 times with TBS plus 0.1% Tween
20, the protein was visualized with an enhanced chemi-
luminescence (ECL) detection system (Amersham Phar-
macia Biotech, Little Chalfont, UK).
Statistical Analysis
All results were expressed as means+ standard error of the
mean (SEM). Statistical analyses were conducted using the
premier vendor for Statistical Package for Social Sciences
(SPSS) Version 23.0 (SPSS Inc, Chicago, IL, USA). Nonpara-
metric statistical analysis such as Mann–Whitney U test was
used for the comparison of 2 groups. Student t test was used
to confirm statistical results. Results with P value < 0.05 was
considered statistically significant.
Results
Gene Expression Profile
Total RNA was prepared from samples obtained from the
bilateral cerebrum after SCI. Next we performed transcrip-
tome analysis by RNA sequencing in order to identify gene
differentially expressed at different phases. Heat map profile
of mRNA expression displaying differentially regulated
transcripts is shown in Fig. 1A. Color key and z-score show
relative expression level of the samples. Red is maximum
and green represents minimum expression levels of the
samples.
Upregulated and downregulated genes (1.5-fold) were
counted and summarized in Fig. 1B. We identified 78
DEGs, 50 DEGs were upregulated and 28 DEGs were
downregulated, in the 3 h post-SCI brain compared to sham
control brain. Furthermore, 383 DEGs, 201 upregulated
DEGs and 182 downregulated DEGs, were identified in 2
wk post-SCI brain expression compared to sham control
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brain expression. Moreover, 316 DEGs—132 upregulated
DEGs and 184 downregulated DEGs—were identified in 2
wk post-SCI brain expression compared to 3-h post-SCI
brain.
Enriched KEGG Pathway Analysis
In order to analyze pathways, total DEGs were classified
based on information regarding gene function using KEGG
pathway database from DAVID. These results were
statistically significant (P < 0.05) and demonstrated in
Table 2.
At acute phase, we observed enriched KEGG path-
ways including oxidative phosphorylation compared to
sham control. At subacute phase, there was cytokine–
cytokine receptor interaction, chemokine signaling path-
way, and antigen processing and presentation compared
to sham control. Compared to acute phase, enriched
KEGG pathways such as antigen processing and presen-
tation, mitogen-activated protein kinase (MAPK)
signaling pathway, and cytokine–cytokine receptor inter-
action were altered in subacute phase. Each upregulated
and downregulated genes was counted and summarized
in Fig. 1C to E.
Validation of Transcriptome Data Using qRT-PCR
and Western Blot
To validate the altered gene expression (fold change j1.5j),
we performed qRT-PCR and Western blot at different
phases. To support the reliability and accuracy of the
RNA-seq expression results, we first performed qRT-PCR,
and Western blot was conducted for further validation. Each
validated DEGs involved in enriched KEGG pathways was
summarized in Table 3.
In oxidative phosphorylation, ATP60C was increased
(1.35-fold, P ¼ 0.0133) whereas COX7B was decreased
(1.96-fold, P ¼ 0.0136) significantly in a similar pattern
as transcriptome data at acute phase compared to sham
Figure 1.Gene expression profile by transcriptome analysis. (A) Heat map of the 2-way hierarchical clustering using z-score for normalized
value. The color scheme is based on z-scores, with upregulation in red and downregulation in green. (B) Spinal cord injury (SCI) phases were
classified into 2 phases: acute phase and subacute phase. Differentially expressed genes (DEGs) were identified at acute phase (3 h post-SCI)
compared to sham control, at subacute phase (2 wk post-SCI) compared to sham control, or at subacute phase compared to acute phase.
Bar graphs show the number of DEGs with fold change  j1.5j at different phases (P < 0.05). (C) Oxidative phosphorylation is an enriched
Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway at acute phase. (D) Cytokine–cytokine receptor interaction, chemokine
signaling pathway, and antigen processing and presentation are enriched KEGG pathways at subacute phase. (E) Antigen processing and
presentation, mitogen-activated protein kinase (MAPK) signaling pathway, and cytokine–cytokine receptor interaction are enriched KEGG
pathways at subacute phase compared to acute phase.
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control (Fig. 2A). Western blot also exhibited same pattern
as qRT-PCR: ATP6V0C (1.6-fold, P ¼ 0.0013) and COX7B
(0.5247-fold, P ¼ 0.0045; Fig. 2B, C).
At subacute phase, compared to sham control, 3 upregu-
lated genes (TNFRSF25, CCR5, and CCR6) and 3 downre-
gulated genes (TNFRSF25, CCR5, and CCR6) were
identified in cytokine–cytokine receptor interaction, 3 upre-
gulated genes (GNG11, CCR5, and CCR6) and 2 downregu-
lated genes (CCL17, NFKBIA) were identified in chemokine
signaling pathway, and there were 4 upregulated genes
(HSPA1AB, HSPA5, CALR, and PDIA3) and 1 downregu-
lated gene (H2-L) in antigen processing and presentation.
These genes were determined by qRT-PCR as follows:
TNFRSF25 (5.37-fold, P ¼ 0.0284), HSPA1AB (4.84-fold,
P ¼ 0.0284), CCR6 (3.15-fold, P ¼ 0.0133), CCR5 (2.42-
fold, P ¼ 0.0133), HSPA5 (2.36-fold, P ¼ 0.0284), GNG11
(2.01-fold, P ¼ 0.0133), CALR (1.57-fold, P ¼ 0.0284),
PDIA3 (1.45-fold, P ¼ 0.0136), HGF (1.43-fold, P ¼
0.0133), H2-L (1.60-fold, P ¼ 0.0136), NFKBIA (1.80-
fold, P ¼ 0.0136), CCL17 (2.03-fold, P ¼ 0.0136), and
IL12RB1 (3.10-fold, P ¼ 0.0167; Fig. 3A). Western blot
showed that TNFRSF25 (1.49-fold, P ¼ 0.0044), HSPA1AB
(1.67-fold, P¼ 0.0096), and HSPA5 (1.43-fold, P¼ 0.0359)
proteins were increased, although NFKBIA was decreased
(0.049-fold, P ¼ 0.0059) significantly at subacute phase
compared to sham control (Fig. 3B, C).
At subacute phase, compared to acute phase, there were 3
enriched KEGG pathways such as antigen processing and
presentation, MAPK signaling pathway, and cytokine–cyto-
kine receptor interaction. Two upregulated genes (HSPA1AB
and HSPA5) and three downregulated genes (H2-T22, LTA,
and H2-K1) were detected in antigen processing and presen-
tation. Six upregulated genes (HSPA1AB, HSPB1, JMJD7,
FGFR2, RASGRP3, and DDIT3) and three downregulated
genes (DUSP5, MAP3K6, and PLA2G3) were detected in
MAPK signaling pathway. Finally, there were 3 upregulated
genes (DUSP5, MAP3K6, and PLA2G3) and 3 downregu-
lated genes (IL12RB1, LTA, and CCL17) in cytokine–cyto-
kine receptor interaction. These genes were determined by
qRT-PCR as follows: TNFRSF25 (5.79-fold, P ¼ 0.0284),
HSPA1AB (5.09-fold, P ¼ 0.0284), HSPB1 (2.12-fold, P ¼
0.0284), CCR5 (1.99-fold, P ¼ 0.0136), HSPA5 (1.94-fold,
P ¼ 0.0133), DDIT3 (1.76-fold, P ¼ 0.0284), FGFR2 (1.69-
fold, P ¼ 0.0284), CX3CR1 (1.62-fold, P ¼ 0.0133),
RASGRP3 (1.55-fold, P ¼ 0.0284), JMJD7 (1.43-fold, P ¼
0.0133), H2-T22 (1.60-fold, P ¼ 0.0136), DUSP5 (1.61-
fold, P ¼ 0.0133), CCL17 (1.97-fold, P ¼ 0.0133), H2-K1
(2.58-fold, P ¼ 0.0177), LTa (3.81-fold, P ¼ 0.0133),
IL12RB1 (4.7-fold, P ¼ 0.0295), PLA2G3 (4.80-fold,
P ¼ 0.0152), and MAP3K6 (6.67-fold, P ¼ 0.0133;
Fig. 4A). According to Western blot results, TNFRSF25
(2.48-fold, P ¼ 0.0004), HSPA1AB (1.98-fold, P ¼ 0.0004),
Table 2. The Enriched KEGG Pathways at Different Phases.
Term Count % P Value Genes
Acute phase compared to sham control
mmu00190: Oxidative phosphorylation 3 4.688 0.049 COX7B2, COX7B, ATP6V0C
Subacute phase compared to sham control
mmu04060: Cytokine–cytokine
receptor interaction
11 2.967 0.010 CCR6, IL12RB1, CCR5, GM13305, TNFRSF25, CX3CR1, CCL21A, HGF,
GM1987, PRL, CCL17
mmu04062: Chemokine signaling
pathway
9 2.374 0.019 CCR6, CCR5, CX3CR1, CCL21A, NFKBIA, GNG11, FOXO3,
GM1987, CCL17
mmu04612: Antigen processing and
presentation
6 1.484 0.047 H2-L, PDIA3, HSPA1A, HSPA1B, HSPA5, CALR
Subacute phase compared to acute phase
mmu04612: Antigen processing and
presentation
7 2.083 0.010 H2-K1, H2-T22, HSPA1A, H2-T23, HSPA1B, HSPA5, LTa
mmu04010: MAPK signaling pathway 11 3.472 0.014 DUSP5, FGFR2, MAP3K6, RASGRP3, JMJD7, FGF11, HSPB1, HSPA1A,
HSPA1B, PLA2G3, DDIT3
mmu04060: Cytokine–cytokine
receptor interaction
9 3.125 0.024 CCL12, IL12RB1, CCR5, GM13305, TNFRSF25, CX3CR1, PRL, LTa, CCL17
Abbreviations: These pathways are statistically significant (P < 0.05). KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein
kinase; COX7B2, Cytochrome c oxidase subunit VIIb2; ATP6V0C, ATPase, H+ transporting V0 subunit C; COX7B, Cytochrome c oxidase subunit VIIb;
TNFRSF25, Tumor necrosis factor receptor superfamily member 25 isoform 1 precursor; CCR5, Chemokine (C-C motif) receptor 5; CCR6, Chemokine (C-C
motif) receptor 6; HGF, Hepatocyte growth factor isoform 3 preproprotein; IL12RB1, Interleukin 12 receptor, beta 1; CCL17, Chemokine (C-C motif) ligand
17; GNG11, Guanine nucleotide binding protein (G protein), gamma 11; NFKBIA, Nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor,
alpha; HSPA1AB, Heat shock protein 1AB; HSPA5, Heat shock protein 5; CALR, Calreticulin; PDIA3, Protein disulfide isomerase associated 3; H2-L, Histo-
compatibility 2, D region locus L; H2-T22, Histocompatibility 2, T region locus 22; LTa, Lymphotoxin A; H2-K1, Histocompatibility 2, K1, K region; HSPB1,
Heat shock protein 1; JMJD7, Jumonji domain containing 7; FGFR2, Fibroblast growth factor receptor 2; RASGRP3, RAS, guanyl releasing protein 3; DDIT3,
DNA damage-inducible transcript 3 protein; DUSP5, Dual specificity phosphatase 5; MAP3K6, Mitogen-activated protein kinase kinase kinase 6; PLA2G3,
Phospholipase A2, group III; CX3CR1, Chemokine (C-X3-C motif) receptor 1; GM13305, Predicted gene 13305; CCL21A, Chemokine (C-C motif) ligand 21A
(serine); GM1987, Predicted gene 1987; PRL, Prolactin; FOXO3, Forkhead box O3; H2-T23, Histocompatibility 2, T region locus 23; FGF11, Fibroblast growth
factor 11 isoform 2; CCL12, Chemokine (C-C motif) ligand 12.
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andHSPA5 (1.45-fold, P¼ 0.0196) proteins were increased sig-
nificantly at subacute phase compared to acute phase (Fig. 4B,C).
Validated enriched KEGG pathways were shown in Fig. 5.
Discussion
Although several studies have shown that SCI may affect
brain,11,12 the underlying pathophysiological mechanisms
have not been completely elucidated. The main purpose of
the present study is to evaluate the gene expression profiling
in the brain after SCI. Based on a previous report focusing on
time point post-injury in a mouse model of SCI30, we sys-
temically characterized the brain after SCI at acute phase (3
h post-injury) and subacute phase (2 wk post-injury). The
different gene expressions and associated enriched KEGG
pathways were analyzed and validated to elucidate the pro-
gression of pathophysiological mechanism in the brain after
SCI.
Table 3. Validated DEGs Involved in Enriched KEGG Pathways at Different Phases.
Pathway Gene Symbol Gene Description Fold Change
Acute phase compared to sham control
Oxidative phosphorylation ATP6V0C ATPase, Hþ transporting V0 subunit C 6.34
COX7B Cytochrome c oxidase subunit VIIb 1.59
Subacute phase compared to sham control
Cytokine–cytokine receptor
interaction
TNFRSF25 Tumor necrosis factor receptor superfamily member 25 isoform 1
precursor
2.7
CCR5 Chemokine (C-C motif) receptor 5 1.7
CCR6 Chemokine (C-C motif) receptor 6 1.6
HGF Hepatocyte growth factor isoform 3 preproprotein 1.5
IL12RB1 Interleukin 12 receptor, beta 1 1.6
CCL17 Chemokine (C-C motif) ligand 17 2.0
Chemokine signaling pathway GNG11 Guanine nucleotide binding protein (G protein), gamma 11 2.0
CCR5 Chemokine (C-C motif) receptor 5 1.7
CCR6 Chemokine (C-C motif) receptor 6 1.6
CCL17 Chemokine (C-C motif) ligand 17 2.0
NFKBIA Nuclear factor of kappa light polypeptide gene enhancer in B cells
inhibitor, alpha
2.1
Antigen processing and
presentation
HSPA1AB Heat shock protein 1AB 3.9
HSPA5 Heat shock protein 5 2.4
CALR Calreticulin 1.6
PDIA3 Protein disulfide isomerase associated 3 1.5
H2-L Histocompatibility 2, D region locus L 1.8
Subacute phase compared to acute phase
Antigen processing and
presentation
HSPA1AB Heat shock protein 1AB 3.3
HSPA5 Heat shock protein 5 2.1
H2-T22 Histocompatibility 2, T region locus 22 1.6
LTa Lymphotoxin A 1.6
H2-K1 Histocompatibility 2, K1, K region 1.7
MAPK signaling pathway HSPA1AB Heat shock protein 1AB 3.3
HSPB1 Heat shock protein 1 2.5
JMJD7 Jumonji domain containing 7 1.8
FGFR2 Fibroblast growth factor receptor 2 1.7
RASGRP3 RAS, guanyl releasing protein 3 1.6
DDIT3 DNA damage-inducible transcript 3 protein 1.6
DUSP5 Dual specificity phosphatase 5 1.7
MAP3K6 Mitogen-activated protein kinase kinase kinase 6 2.3
PLA2G3 Phospholipase A2, group III 3.6
Cytokine–cytokine receptor
interaction
TNFRSF25 Tumor necrosis factor receptor superfamily member 25 isoform 1
precursor
3.2
CX3CR1 Chemokine (C-X3-C motif) receptor 1 1.8
CCR5 Chemokine (C-C motif) receptor 5 1.6
IL12RB1 Interleukin 12 receptor, beta 1 1.6
LTa Lymphotoxin A 1.6
CCL17 Chemokine (C-C motif) ligand 17 2.1
Abbreviations: DEG, differentially expressed gene; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase.
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Figure 3. Validation using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and Western blot at subacute
phase. (A) TNFRSF25, HSPA1AB, CCR6, CCR5, HSPA5, GNG11, CALR, and PDIA3 are significantly upregulated and HGF, H2-L, NFKBIA, CCL17, and
IL12RB1 are significantly downregulated at subacute phase. These genes are involved in cytokine–cytokine receptor interaction, chemokine
signaling pathway, and antigen processing and presentation (n¼ 3 per group; *P < 0.05). The relative expression of target genes from qRT-PCR
was calculated using 2DDCT method. All results were expressed as means + standard error of the mean. (B) Western blot analysis was
performed using antibodies against TNFRSF25, HSPA1AB, HSPA5, NFKBIA, and ACTIN (as control). (C) Comparison of relative protein expression
from the brain between sham control and 2 wk post–spinal cord injury verified by Western blot. RNA sequencing, RNA-Seq; ATP6V0C,
ATPase, H+ transporting V0 subunit C; COX7B, TNFRSF25, Tumor necrosis factor receptor superfamily member 25 isoform 1 precursor;
CCR5, Chemokine (C-C motif) receptor 5; CCR6, Chemokine (C-C motif) receptor 6; IL12RB1, Interleukin 12 receptor, beta 1; CCL17,
Chemokine (C-C motif) ligand 17; GNG11, Guanine nucleotide binding protein (G protein), gamma 11; NFKBIA, Nuclear factor of kappa light
polypeptide gene enhancer in B cells inhibitor, alpha; HSPA1AB, Heat shock protein 1AB; HSPA5, Heat shock protein 5; CALR, Calreticulin;
PDIA3, Protein disulfide isomerase associated 3; H2-L, Histocompatibility 2, D region locus L. *P < 0.05. **P < 0.01.
Figure 2. Validation using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and Western blot at acute
phase. (A) RNA sequencing, RNA-Seq; ATP6V0C is significantly upregulated and COX7B, Cytochrome c oxidase subunit VIIb is significantly
downregulated in oxidative phosphorylation pathway at acute phase (n ¼ 3 per group; *P < 0.05). The relative expression of target genes
from qRT-PCR were calculated using 2DDCT method. All results were expressed as means+ standard error of the mean. (B)Western blot
analysis was performed using antibodies against ATP6V0C, COX7B, and ACTIN (as control). (C) Comparison of relative protein expression
from the brain between sham control and 3 h post–spinal cord injury verified by Western blot. **P < 0.01.
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In the acute phase, ATP6V0C was upregulated due to
oxidative phosphorylation, compared to sham control, while
COX7B was downregulated by RNA-seq, qRT-PCR (Table
3; Fig. 2A), and Western blot (Fig. 2B, C). Oxidative phos-
phorylation is an effective metabolic pathway that provides
energy by adenosine triphosphate (ATP) synthesis in the
mitochondria of cells.31,32 There are 5 main protein com-
plexes in the electron transport chain, which are nicotina-
mide adenine dinucleotide hydride (NADH) dehydrogenase
(complex I), succinate dehydrogenase (complex II), cyto-
chrome bc1 complex (complex III), cytochrome c oxidase
(complex IV), and ATP synthase (complex V). The upregu-
lation of ATP6V0C and downregulation of COX7B resulted
in impaired oxidative phosphorylation, which could increase
mitochondrial reactive oxygen species (ROS) production
from electron transport chain complexes. The CNS has high
oxygen consumption, hence particularly susceptible to ROS-
induced damage.33,34 Mitochondrial dysfunction and
impaired oxidative phosphorylation may play an important
role in the pathogenesis of brain injury after SCI, especially
at acute phase.
At subacute phase, cytokine–cytokine receptor interac-
tion (upregulation: TNFRSF25, CCR5, and CCR6; downre-
gulation: HGF and IL12RB1), chemokine signaling pathway
(upregulation: GNG11, CCR5, and CCR6; downregulation:
CCL17 and NFKBIA), and antigen processing and presenta-
tion pathways (upregulation: HSPA1AB, HSPA5, CALR, and
PDIA3; downregulation: H2-L) were activated by RNA-seq
Figure 4. Validation using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) and Western blot at subacute
phase compared to acute phase. (A) TNFRSF25, HSPA1AB, HSPB1, CCR5, HSPA5, DDIT3, FGFR2, CX3CR1, RASGRP3, and JMJD7 are significantly
upregulated and H2-T22, DUSP5, CCL17, H2-K1, LTa, IL12RB1, PLA2G3, and MAP3K6 are significantly downregulated subacute phase. These
genes are involved in cytokine–cytokine receptor interaction, chemokine signaling pathway, and antigen processing and presentation (n ¼ 3
per group; *P < 0.05). The relative expression of target genes from qRT-PCR were calculated using 2DDCT method. All results were
expressed as means+ standard error of the mean. (B) Western blot analysis was performed using antibodies against TNFRSF25, HSPA1AB,
HSPA5, and ACTIN (as control). (C) Comparison of relative protein expression from the brain between 3 h post–spinal cord injury (SCI) and
2 wk post-SCI verified by Western blot. TNFRSF25, Tumor necrosis factor receptor superfamily member 25 isoform 1 precursor; CCR5,
Chemokine (C-C motif) receptor 5; IL12RB1, Interleukin 12 receptor, beta 1; CCL17, Chemokine (C-C motif) ligand 17; HSPA1AB, Heat
shock protein 1AB; HSPA5, Heat shock protein 5; CALR, Calreticulin; PDIA3, Protein disulfide isomerase associated 3; H2-L, Histocompat-
ibility 2, D region locus L; H2-T22, Histocompatibility 2, T region locus 22; LTa, Lymphotoxin A; H2-K1, Histocompatibility 2, K1, K region;
HSPB1, Heat shock protein 1; JMJD7, Jumonji domain containing 7; FGFR2, Fibroblast growth factor receptor 2; RASGRP3, RAS, guanyl
releasing protein 3; DDIT3, DNA damage-inducible transcript 3 protein; DUSP5, Dual specificity phosphatase 5; MAP3K6, Mitogen-
activated protein kinase kinase kinase 6; PLA2G3, Phospholipase A2, group III; CX3CR1, Chemokine (C-X3-C motif) receptor 1.
*P < 0.05, ***P < 0.001.
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(Table 3; Fig. 3). Furthermore, antigen processing and pre-
sentation (upregulation: HSPA1AB and HSPA5; downregu-
lation: H2-T22, LTa, and H2-K1) and cytokine–cytokine
receptor interaction pathways (upregulation: TNFRSF25,
CX3CR1, and CCR5; downregulation: IL12RB1, LTa, and
CCL17) were also elevated at subacute phase compared to
acute phase (Table 3; Fig. 4).
Cytokines and chemokines are very important for CNS
immune system interactions. In the nervous system, they
function as neuromodulators and regulate neurodevelop-
ment, neuroinflammation, and synaptic transmission. In the
brain, cytokines and chemokines are crucial for immune
response such as maintaining immunological surveillance,
leukocyte traffic modulation, and other inflammatory factor
recruitment.35,36 TNFRSF25 is one of the proinflammatory
members, which can stimulate T lymphocyte, B lymphocyte,
and antigen presenting cells.37 TNFSF25 can induce nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-
kB) via tumor necrosis factor receptor type 1–associated
death domain protein (TRADD) and Tumor necrosis factor
(TNF) receptor–associated factor 2 (TRAF2).38 CCR5 is one
of the members of chemokine receptor family and plays an
important role in the pathogenesis of brain injury and neu-
rodegenerative disorders.39,40 CCR6 is one of the chemokine
Figure 5. Illustration of the validated Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. (A) Oxidative phosphorylation
pathway. Red stars denote the enriched genes. (B) Cytokine–cytokine receptor interaction pathway. Orange stars denote the enriched
genes at subacute phase. Red stars denote the enriched genes at subacute phase compared to acute phase. (C) Chemokine signaling
pathway. Orange stars denote the enriched genes at subacute phase. (D) Antigen processing and presentation pathway. Orange stars denote
the enriched genes at subacute phase. Red stars denote the enriched genes at subacute phase compared to acute phase. (E) Mitogen-
activated protein kinase signaling pathway. Red stars denote the enriched genes at subacute phase compared to acute phase. These pathways
mapping were provided from the KEGG pathways of Database for Annotation Visualization, and Integrated Discovery functional annotation
tool (DAVID v6.7; http://david.abcc.ncifcrf.gov/).
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receptors that can bind to a single chemokine ligand, CCL20.
CCL20/CCR6 is important for the trafficking of T cells to the
CNS across the choroid plexus during immune surveillance
as well as neuroinflammation.41 GNG11, membrane bound
G-protein subunit, is induced by oxidative stress and may
regulate cell senescence.42 CX3CR1 is a receptor of the che-
mokine fractalkine (CX3CL1). CX3CL1/CX3CR1 axis can
regulate the maintenance of the communication between
neuron and microglia in health and disease.36,43 Especially
in the brain of mice, ischemic condition might stimulate
neurons to release CX3CL1 and microglia to express
CX3CR1.44 The interaction of CX3CL1/CX3CR1 increased
in the brain of ischemic mice. HGF is an angiogenic growth
factor, which prevents the extension of several ischemic
injuries.45-48 NFKBIA encodes IkBa, negative regulator of
transcription factor NF-kB, which regulates proinflamma-
tory cytokines, chemokines, and is also related to prosurvival
and antiapoptosis.49-51 IL-12 receptor (IL-12R) has 2 subu-
nits, b1 and b2, which are required to bind IL-12 for high
affinity. The signaling function of IL-12Rb1 has not been
revealed yet, but it may be needed to maintain high affinity
binding with cytokine.44 LTa, a proinflammatory cytokine
with homology to tumor necrosis factor alpha (TNFa), has
not been investigated clearly but may contribute to inflam-
matory processes.52 CCL17 is a small cytokine, also known
as thymus and activation regulation chemokine. CCL17
binds and induces chemotaxis in T cells that may associate
with inflammation.53,54 Thus, neuroinflammation in the
brain after SCI may induce activation of cytokine–cytokine
receptor interaction, chemokine signaling pathway at sub-
acute phase compared to sham control, as well as cytokine–
cytokine receptor interaction also have a role at subacute
phase compared to acute phase.
Antigen processing and presentation pathway was acti-
vated at subacute phase compared to sham control as fol-
lows, upregulation: HSPA1AB, HSPA5, CALR, and PDIA3;
downregulation: H2-L (Table 3; Fig. 3), and also activated at
subacute phase compared to acute phase as follows—upre-
gulation: HSPA1AB and HSPA5; downregulation: H2-T22,
LTa, and H2-K1 (Table 3; Fig. 4).
Endoplasmic reticulum (ER) stress not only plays vital
role in mediating ischemic neuronal cell death but also med-
iates pathophysiological reactions in brain injuries.55 ER
stress could modulate dysregulation of Major
Figure 6. Summary of transcriptomic changes in the brain after spinal cord injury (SCI). In the brain after SCI, A; mitochondria function
impairs at acute phase (3 h post-injury), B; while inflammatory response and endoplasmic reticulum (ER) stress occur at subacute phase
(2 wk post-injury). These cascades lead to the activation of mitogen-activated protein kinase (MAPK) signaling pathway. These mechanisms
suggest that SCI and brain injury are closely associated with each other.
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histocompatibility complex I (MHC I) peptide presentation
during infected and transformed cells by cluster of differen-
tiation 8 (CD 8) T lymphocytes.56 The connection between
presentation of MHC I-associated peptides and CD8 T cells
is tight. MHC I peptides are primarily generated by de novo
synthesis and degraded rapidly.56-58 Following proteasomal
degradation, peptides are translocated into ER. The ER
responds to the accumulating unfolded proteins by activating
intracellular signal transduction pathways called the
unfolded protein response (UPR). UPR can regulate MHC
I peptide processing, protein translocation, and degradation.
Therefore, ER stress affects MHC I peptide presentation.
During ER stress, dysregulation of MHC I presentation leads
to impaired presentation of peptides derived from proteins.56
HSPA1AB and HSPA5 play multiple roles in cellular home-
ostasis. Their expressions are significantly increased in sev-
eral types of stress conditions and lead to reduced RNA
translation and enhanced the degradation of misfolded pro-
teins.59,60 CALR, as a modulator of the Caþþ balance, is
located mostly in the lumen of the ER. During ER stress,
CALR expression is upregulated and transferred to outside
the cell.61,62 PDIA3, a member of ER stress proteins, can be
induced by oxidative stress conditions. PDIA3 is mediated
by redox-sensitive transcription factors, in cellular response
to oxidative stress.63,64 Therefore, ER stress in the brain after
SCI may be induced by the activation of antigen processing
and presentation at subacute phase compared to sham control
and acute phase.
MAPK signaling pathway plays a vital role in ER stress,
which was activated at subacute phase as follows—upregu-
lation: HSPA1AB, HSPB1, JMJD7, FGFR2, RASGRP3, and
DDIT3; downregulation: DUSP5, MAP3K6, and PLA2G3
(Table 3; Fig. 4). MAPK signaling pathway is activated in
response to ER stress and UPR.65 Particularly, Heat shock
proteins (HSPs) are constitutively expressed in certain cell
types and are also induced upon exposure of cells to elevated
temperatures and other cell stress environments.66 In MAPK
pathway, phosphorylated HSPB1 plays a key role in the
induction of several genes related to inflammatory response.
The signaling components of the Fibroblast growth factor
(FGF) family interact with tyrosine kinase fibroblast growth
factor receptors (FGFRs). FGFRs activation leads to phos-
phorylation of specific tyrosine residues, mediates interac-
tion of cytosolic adaptor proteins, and regulates several
intracellular signaling pathways, such as RAS-MAPK,
phosphatidylinositol 3-kinase (PI3K)-AKT, phospholipase
C gamma (PLC gamma), and signal transducer and activator
of transcription (STAT).67 Activation of FGFR2 may regu-
late MAPK signaling. In response to ER stress, MAPK sig-
naling pathway is activated in the brain after SCI at subacute
phase compared to acute phase.
Taken together, we focused on the brain after SCI
pathophysiological events. Our study suggested that gene
expression change plays an important role in the pathophy-
siological process of the injury, and SCI also affects brain
injury. In addition, individual genes, which involved in
enriched KEGG pathways, will be considered reliable mole-
cular markers in the brain after cell-based therapy in SCI. In
further study, investigation should be extended to provide
neurobiological mechanism for association between brain
and spinal cord. This gene expression change may contribute
to new mechanisms and therapeutic targets for CNS
disorders.
Conclusions
Our study provided gene expression patterns in the brain
after SCI in pathophysiological processes (acute phase and
subacute phase). In the brain after SCI, mitochondria dys-
function occurred at acute phase, followed by inflammatory
response and ER stress aroused at subacute phase. Finally,
these stress environments led to the activation of MAPK
signaling pathway at subacute phase (Fig. 6). These patho-
physiological mechanisms have already been reported in
SCI.68-70 Our results emphasized that SCI is closely associ-
ated with brain injuries. Hence, these mechanisms may pro-
vide not only a link between SCI and brain injury but also
valuable reference data for understanding gene expression
patterns at acute phase and subacute phase.
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